Assessment of Abuse Potential of Rapastinel in Humans

NCT ID: NCT03799900

Last Updated: 2019-05-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-11-01
• Study Completion Date: 2019-03-29

Brief Summary

Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.

Conditions

Human Abuse Potential

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: DOUBLE

Study Groups

Part 2, Treatment Phase: Rapastinel High Dose

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Group Type: EXPERIMENTAL

Rapastinel

Intervention Type: DRUG

During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Part 2, Treatment Phase: Ketamine

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Group Type: ACTIVE_COMPARATOR

Ketamine

Intervention Type: DRUG

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Part 2, Treatment Phase: Placebo

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Part 1, Cohort 1: Ketamine Low Dose

Some participants will be administered a single IV dose of ketamine on Day 1.

Group Type: EXPERIMENTAL

Ketamine

Intervention Type: DRUG

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Part 1, Cohort 1: Placebo

Some participants will be administered a single IV dose of placebo on Day 1.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Part 1, Cohort 2: Ketamine Medium Dose

Some participants will be administered a single IV dose of ketamine on Day 1.

Group Type: EXPERIMENTAL

Ketamine

Intervention Type: DRUG

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Part 1, Cohort 2: Placebo

Some participants will be administered a single IV dose of placebo on Day 1.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Part 1, Cohort 3 (Optional): Ketamine High Dose

Optional: some participants will be administered a single IV dose of ketamine on Day 1.

Group Type: EXPERIMENTAL

Ketamine

Intervention Type: DRUG

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Part 1, Cohort 3 (Optional): Placebo

Optional: some participants will be administered a single IV dose of placebo on Day 1.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Part 2, Qualification Phase: Ketamine

Participants will receive IV ketamine on Day 1 and placebo on Day 2 in a randomized crossover manner.

Group Type: EXPERIMENTAL

Ketamine

Intervention Type: DRUG

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Part 2, Qualification Phase: Placebo

Participants will receive IV ketamine on Day 2 and placebo on Day 1 in a randomized crossover manner.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Part 2, Treatment Phase: Rapastinel Low Dose

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Group Type: EXPERIMENTAL

Rapastinel

Intervention Type: DRUG

During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Part 2, Treatment Phase: Rapastinel Medium Dose

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Group Type: EXPERIMENTAL

Rapastinel

Intervention Type: DRUG

During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Interventions

Rapastinel

During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Intervention Type: DRUG

Ketamine

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Intervention Type: DRUG

Placebo

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participant must be a current recreational polydrug user
• Have a supine systolic blood pressure (BP) ≥ 95 mm Hg and ≤ 145 mg Hg, or supine diastolic BP ≥ 50 mm Hg and ≤ 90 mm Hg at the Screening Visit.
• Have negative test results for benzoylecgonine (cocaine), methadone, barbiturates, amphetamines, benzodiazepines, alcohol, oxycodone and other opioids, and phencyclidine at any admission
• Able, as assessed by the investigator, and willing to follow study instructions and likely to complete all required study visits

Exclusion Criteria

• Evidence of drug or alcohol dependence (excluding nicotine and caffeine) within the past 2 years
• Suicidal risk based on the opinion of the principal investigator (or appropriately trained designee)
• History of violent or psychotic behavior when taking psychedelic drugs, or unwilling to take a drug that might alter perception in a controlled setting
• Have taken or require concomitant treatment with any CNS depressants, or cannot safely discontinue these medications within 14 days (or 5 half-lives, whichever is longer) before study treatment administration
• Previously participated in an investigational study of rapastinel.
• Participation in any other clinical investigation using an experimental drug within 30 days, 5 half-lives or twice the duration of the biological effect of the study treatment (whichever is longer), prior to study treatment administration or is concurrently enrolled in any clinical trial, judged not to be scientifically or medically compatible with this study
• Consumption of alcohol within 72 hours before administration of study treatment
• Breastfeeding
• Unable to refrain from consuming caffeine or xanthine-containing compounds such as tea, coffee, soft drinks, energy sports drinks or chocolate (more than 48 oz/day) from 48 hours before administration of study treatment.
• Have consumed dietary supplements or other foods or beverages that may affect various drug metabolizing enzymes and transporters (eg, grapefruit, grapefruit juice, grapefruit-containing beverages), vegetables from the mustard green family (eg, kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard), and charbroiled meats within 14 days prior to dosing or unable to refrain from consumption during the study.
• The ability to tolerate IV ketamine as judged by the Investigator, based on available safety data, as well as pharmacodynamic data.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Naurex, Inc, an affiliate of Allergan plc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sheng Fang Su

Role: STUDY_DIRECTOR

Allergan

Locations

Vince and Associates Clinical Research Inc

Overland Park, Kansas, United States

Countries

United States

Other Identifiers

RAP-PK-12

Identifier Type: -

Identifier Source: org_study_id